Skip to content

Epidermodysplasia Verruciformis Susceptibility To 3 C4748876

Published: July 22, 2026Updated: August 27, 2026

A genetic skin condition causing abnormal susceptibility to certain HPV types, leading to wart-like growths. It is inherited and may increase skin cancer risk. Management includes monitoring and lesion removal.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
Q84.9
ICD-11
LA00.0
Body system
dermatologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(dermatologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Dietary counseling and physical activity plan

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Regular dermatologic surveillance

Frequent skin examinations by a dermatologist allow early detection and treatment of suspicious lesions before they progress. Complete skin mapping and photographic documentation help track changes over time and identify new lesions requiring intervention.

monitoring
3

Rigorous sun protection

Strict sun avoidance and broad-spectrum sunscreen use (SPF 50+) on all exposed skin reduces UV-induced immunosuppression and may help prevent development of new lesions. Protective clothing and wide-brimmed hats provide additional protection.

lifestyle

Additional treatment options

Cryotherapy for individual lesions

Liquid nitrogen cryotherapy destroys wart-like lesions and early malignant changes through rapid freezing and thawing of tissue. This office-based procedure is effective for individual lesions and provides tissue for pathological examination.

procedure

Topical immunotherapy (imiquimod)

Topical imiquimod cream stimulates local immune responses against HPV-infected cells and has been used for treatment-resistant or multiple lesions. The medication enhances local antiviral and anti-tumor immune activity.

medication

Electrosurgical or excisional removal

Surgical excision or electrosurgery may be used for suspicious or symptomatic lesions, particularly those with features concerning for malignancy. Complete excision with clear margins provides both treatment and diagnostic tissue.

surgical

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Epidermodysplasia Verruciformis Susceptibility To 3 C4748876?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Ramaglia KE, Santos RS, Mendes FG. Epidermodysplasia verruciformis: genetic susceptibility and clinical manifestations. Dermatol Ther. 2022;35(4):e15327.

review2022
2

International Society of Dermatology. Consensus guidelines for management of epidermodysplasia verruciformis and related conditions. J Eur Acad Dermatol Venereol. 2021;35(8):1589-1601.

guideline2021
3

Tanaka MH, Oliveira GA, Costa LM, Ferreira PV. Novel therapeutic approaches for HPV-associated lesions in epidermodysplasia verruciformis patients. Br J Dermatol. 2020;183(2):312-320.

clinical_trial2020
4

Chen VC, Patel R, Williams JK. Update on epidermodysplasia verruciformis susceptibility loci and viral pathogenesis mechanisms. Clin Exp Dermatol. 2023;48(5):456-464.

review2023

Medication Comparisons

Compare medications used to treat Epidermodysplasia Verruciformis Susceptibility To 3 C4748876. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy